Table 2 |
|||
|
Multivariate models predicting new carotid plaque formation in nondiabetic patients with rheumatoid arthritis over 3.6 ± 0.2 yearsa |
|||
|
New carotid plaque formation during follow-up (yes vs no) |
|||
|
|
|||
|
Parameters |
β coefficient |
P value |
Odds ratio (95% CI) |
|
|
|||
|
Model 1: traditional CV risk factors (r2 = 0.0453) |
|||
|
Age at follow-up end (years) |
0.146 |
0.004 |
5.752b (1.770 to 18.694) |
|
Sex |
0.038 |
0.970 |
0.963b (0.134 to 6.927) |
|
Total years of smoking (at follow-up end) |
0.051 |
0.023 |
2.628b (1.145 to 6.029) |
|
SBP AUC (mmHg × months) |
0.001 |
0.346 |
1.495b (0.648 to 3.449) |
|
LDL AUC (mg/dl × months) |
0.000 |
0.126 |
0.507b (0.212 to 1.211) |
|
BMI (at follow-up end) |
0.088 |
0.356 |
1.445b (0.661 to 3.160) |
|
Model 3 RA treatment (months of treatment during follow-up) (r2 = 0.248) |
|||
|
Corticosteroids |
0.067 |
0.016 |
3.058 (1.231 to 7.593) |
|
Biologic agents |
-0.035 |
0.046 |
0.502 (0.255 to 0.987) |
|
Nonbiologic DMARDs |
-0.017 |
0.477 |
0.802 (0.437 to 1.473) |
|
Final model (r2 = 0.559)c |
|||
|
Age at follow-up end (years) |
0.136 |
0.006 |
5.098 (1.599 to 16.250) |
|
Total years of smoking (at follow-up end) |
0.055 |
0.009 |
2.875 (1.305 to 6.335) |
|
Corticosteroids (months during follow-up) |
0.086 |
0.016 |
4.170 (1.299 to 13.385) |
|
Biologic agents (months during follow-up) |
-0.033 |
0.118 |
0.520 (0.230 to 1.180) |
|
|
|||
|
aAUC: area under the curve, BMI: body mass index, CV: cardiovascular, DMARDs: disease modifying antirheumatic drugs, LDL: low-density lipoprotein, RA: rheumatoid arthritis, SBP: systolic blood pressure. cOnly the variables from models 1 to 3 that predicted new plaque formation were used in the final model. Model 2 is described in the text only. bThe odds ratio for the continuous values was assessed for 1 SD increase and so is provided by exp(β*SD) (SD for age 12.0, for total years of smoking 19.15, for SBP (AUC) 629.10, for LDL (AUC) 1343.77, for BMI 4.25, for corticosteroid treatment (months during follow-up) 16.60, for biologic agents received (months during follow-up) 19.90, for nonbiologic DMARDs (months during follow-up) 13.20). Dependent variable 0 is subjects with no new plaque (n = 45), variable 1 is subjects with at least one plaque (n = 19) at the end of follow-up (binary logistic regression analysis using enter method is presented, and identical results in all models were obtained using the backward method). |
|||
|
Zampeli et al. Arthritis Research & Therapy 2012 14:R44 doi:10.1186/ar3757 |
|||